Krka, d. d. (LJSE:KRKG)

Market Cap	7.76B +36.4%
Revenue (ttm)	2.08B +7.2%
Net Income	372.00M -9.3%
EPS	11.98 -10.3%
Shares Out	30.30M
PE Ratio	21.38
Forward PE	19.01
Dividend	9.10 (3.55%)
Ex-Dividend Date	Jul 21, 2026

Volume	1,895
Open	256.00
Previous Close	255.00
Day's Range	256.00 - 259.00
52-Week Range	174.00 - 260.00
Beta	0.41
Analysts	Hold
Price Target	210.73 (-17.68%)
Earnings Date	May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 11,667
• Stock Exchange: Ljubljana Stock Exchange
• Ticker Symbol: KRKG

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.

Analyst Summary

According to 6 analysts, the average rating for KRKG stock is "Hold." The 12-month stock price target is €210.73, which is a decrease of -17.68% from the latest price.

Price Target

€210.73

(-17.68% downside)

Analyst Consensus: Hold